- Home
- NBR vs CSTL Comparison
NBR vs CSTL Comparison
Compare NBR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- CSTL
- Stock Information
- Founded
- NBR 1952
- CSTL 2007
- Country
- NBR Bermuda
- CSTL United States
- Employees
- NBR N/A
- CSTL N/A
- Industry
- NBR Oil & Gas Production
- CSTL Medical Specialities
- Sector
- NBR Energy
- CSTL Health Care
- Exchange
- NBR Nasdaq
- CSTL Nasdaq
- Market Cap
- NBR 417.7M
- CSTL 456.2M
- IPO Year
- NBR N/A
- CSTL 2019
- Fundamental
- Price
- NBR $30.31
- CSTL $20.30
- Analyst Decision
- NBR Hold
- CSTL Strong Buy
- Analyst Count
- NBR 8
- CSTL 6
- Target Price
- NBR $44.50
- CSTL $37.67
- AVG Volume (30 Days)
- NBR 545.2K
- CSTL 451.0K
- Earning Date
- NBR 07-29-2025
- CSTL 08-04-2025
- Dividend Yield
- NBR N/A
- CSTL N/A
- EPS Growth
- NBR N/A
- CSTL N/A
- EPS
- NBR N/A
- CSTL N/A
- Revenue
- NBR $2,932,608,000.00
- CSTL $347,083,000.00
- Revenue This Year
- NBR $13.65
- CSTL N/A
- Revenue Next Year
- NBR $5.53
- CSTL $1.36
- P/E Ratio
- NBR N/A
- CSTL N/A
- Revenue Growth
- NBR N/A
- CSTL 38.43
- 52 Week Low
- NBR $23.27
- CSTL $15.45
- 52 Week High
- NBR $105.96
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NBR 53.01
- CSTL 66.24
- Support Level
- NBR $27.33
- CSTL $18.18
- Resistance Level
- NBR $31.73
- CSTL $20.63
- Average True Range (ATR)
- NBR 2.10
- CSTL 0.78
- MACD
- NBR -0.17
- CSTL 0.15
- Stochastic Oscillator
- NBR 38.57
- CSTL 87.97
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.